Neoadjuvant Cytoreductive Treatment of Regionally Advanced Melanoma With BRAF/MEK Inhibition: Study Protocol of the REDUCTOR (Cytoreductive Treatment of Dabrafenib Combined With Trametinib to Allow Complete Surgical Resection in Patients With BRAF Mutated, Prior Unresectable Stage III or IV Melanoma) Trial
Clinical Skin Cancer · 2016
DOI: 10.1016/j.clsc.2016.11.006 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Clinical Skin Cancer, 2016. Verfasst von Max F. Madu und 8 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Madu, M. F., Rozeman, E. L., Hage, J. A. V. D., Wouters, M. W., Klop, W. M. C., Thienen, J. H. V., Blank, C. U., Haanen, J. B., & Akkooi, A. C. V. (2016). Neoadjuvant Cytoreductive Treatment of Regionally Advanced Melanoma With BRAF/MEK Inhibition: Study Protocol of the REDUCTOR (Cytoreductive Treatment of Dabrafenib Combined With Trametinib to Allow Complete Surgical Resection in Patients With BRAF Mutated, Prior Unresectable Stage III or IV Melanoma) Trial. Clinical Skin Cancer. https://doi.org/10.1016/j.clsc.2016.11.006
Vancouver
Madu MF, Rozeman EL, Hage JAVD, Wouters MW, Klop WMC, Thienen JHV, et al. Neoadjuvant Cytoreductive Treatment of Regionally Advanced Melanoma With BRAF/MEK Inhibition: Study Protocol of the REDUCTOR (Cytoreductive Treatment of Dabrafenib Combined With Trametinib to Allow Complete Surgical Resection in Patients With BRAF Mutated, Prior Unresectable Stage III or IV Melanoma) Trial. Clinical Skin Cancer. 2016. doi:10.1016/j.clsc.2016.11.006
BibTeX
@article{Madu2016,
author = {Madu, Max F. and Rozeman, E.A. Lisette and Hage, Jos A. van der and Wouters, Michel W.J.M. and Klop, W. Martin C. and Thienen, J.V. Hans van and Blank, Christian U. and Haanen, John B.A.G. and Akkooi, Alexander C.J. van},
title = {Neoadjuvant Cytoreductive Treatment of Regionally Advanced Melanoma With BRAF/MEK Inhibition: Study Protocol of the REDUCTOR (Cytoreductive Treatment of Dabrafenib Combined With Trametinib to Allow Complete Surgical Resection in Patients With BRAF Mutated, Prior Unresectable Stage III or IV Melanoma) Trial},
journal = {Clinical Skin Cancer},
year = {2016},
doi = {10.1016/j.clsc.2016.11.006}
}
EUVIMED